Kimio Ueno

Profile
Tenure
Apr 1966 – Mar 1987
Years in office
20.9 years
Name in Japanese
上野公夫
Title at appointment
Representative Director, President
Performance in office
Chugai Pharmaceutical
Performance in office
FY1963FY1984Change
Revenue¥11.7billion¥100.2billion+759%
Net margin5.6%4.5%−1.1pt
Juzo UenoKimio UenoSanoNagayama
Revenue¥9.3 billionRevenue¥20.1 billionRevenue¥87.8 billionRevenue¥151.5 billionRevenue¥159.4 billionNet margin5.9%Net margin1%Net margin5%Net margin3.2%Net margin4.3%1962/121967/121972/121977/121982/121987/121992/12
Revenue¥9.3 billionRevenue¥20.1 billionRevenue¥87.8 billionRevenue¥151.5 billionRevenue¥159.4 billionNet margin5.9%Net margin1%Net margin5%Net margin3.2%Net margin4.3%1962/121967/121972/121977/121982/121987/121992/12
Tenure

Tenure

Background

From the finance side, he joined the Bank of Japan in 1941 and moved to Chugai Pharmaceutical in 1953. He became a Director in 1955, Senior Managing Director in 1956 and Executive Vice President in 1958, and had been with the company 13 years when he became President. Shares were concentrated with the founder: in the shareholder register at the end of March 1961, Juzo Ueno was the largest shareholder with 10.7%, and Kimio Ueno ranked seventh with 1.7%.

Education: Keio University, Faculty of Economics (1941)

Selection

In April 1966 he became President, succeeding founder Juzo Ueno. Just before the change, in the fiscal year ended March 1966, poor sales of Gurongsan had driven the company to suspend its dividend and solicit 420 early retirees. Even after the Chugai-kai system was set up in September 1964, excessive competition and consumers holding back on health tonics continued, and sales of pharmacy products declined. The task of ending dependence on a single product appears to have been entrusted to a successor from the finance side.

Initiatives

Research on recombinant DNA drugs, begun in the mid-1970s, had no foreseeable path to profitability, since biotechnology was then still at the basic research stage. In the early 1980s Kimio Ueno, together with Hajime Sano, the executive in charge of R&D, decided to keep investing in this research. "If the management of the time had not decided to continue biotechnology development, today's Chugai would not exist" was the assessment of Osamu Nagayama, who later became President. Net sales grew from ¥20.4 billion in the fiscal year ended March 1971 to ¥100.1 billion in FY ended December 1984.

Career

Career

Bank of Japan

Date Position
1941 Joined

Chugai Pharmaceutical

Date Position
1953 Joined
1955 Director
1956 Senior Managing Officer
1958 Executive Vice President
Apr 1966 Representative Director, President
Mar 1987 Representative Director, Chairman
Mar 1987 Stepped down as President
2000 Honorary Chairman